Patent ID: 7323543

Claim:
A method of treating diabetes comprising the step of administering to a patient in need of such treatment at least two pharmaceutical compositions (a)-(c), wherein: composition (a) comprises: (i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and (ii) a pharmaceutically acceptable carrier, composition (b) comprises: (i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and (ii) a pharmaceutically acceptable carrier, and composition (c) comprises: (i) an insulin sensitizer, and (ii) a pharmaceutically acceptable carrier, and wherein compositions (b) and (c) are required and administered concomitantly and further wherein the compositions administered in the method comprise GLP-1, troglitazone and Genapol 1800.